Schizoaffective disorder: Role of atypical antipsychotics

Schizophrenia Research

Volumn 35, Issue SUPPL., 1999, Pages

  Keck Jr , Paul E ^a   McElroy, Susan L ^a   Strakowski, Stephan M ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Atypical antipsychotics; Clozapine; Olanzapine; Quetiapine; Risperidone; Schizoaffective disorder; Sertindole; Thymoleptic activity; Ziprasidone

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2 RECEPTOR; SERTINDOLE; VALPROATE SEMISODIUM; ZIPRASIDONE;

AFFECTIVE NEUROSIS; CONFERENCE PAPER; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOIDISM; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTIC DISORDERS;

EID: 0344197072     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00165-0     Document Type: Conference Paper

References (56)

1. American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn., revised. American Psychiatric Press, Washington, DC.
2. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington, DC.
3. Aprison, M.H., Takahashi, R., Tachiki, K., 1987. Hypersensitive serotonergic receptors involved in clinical depression - a theory. In: Haber, B., Aprison, M.H. (Eds.), Neuropharmacology and Behavior. Plenum, New York, pp. 23-48.
4. 2 binding sites in the frontal cortex of suicide victims and controls. Am. J. Psychiatry. 146:1989;730-736.
5. Arvanitis, L.A., Miller, B.G., Kowalcyk, B.B. et al., 1997. Efficacy of 'Seroquel' (quetiapine fumarate) in affective symptoms of schizophrenia. In: Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, HI, December 8.
6. Baldessarini R.J., Huston-Lyons D., Campbell A.et al. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br. J. Psychiatry. 160(Suppl. 17):1992;12-16.
7. Banov M.D., Zarate C.A., Tohen M.et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J. Clin. Psychiatry. 55:1994;295-300.
8. 2 receptor binding on blood platelets - a peripheral marker for depression? Life Sci. 41:1987;2485-2492.
9. Blackshear M.A., Sanders-Bush E. Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J. Pharmacol. Exp. Ther. 221:1982;303-308.
10. Brockington I.F., Kendall R.E., Kellett J.M.et al. Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br. J. Psychiatry. 133:1978;162-168.
11. Bymaster F.P., Calligaro D.O., Falcone J.F.et al. Radio receptor binding profile of the atypical antipsychotic clozapine. Neuropsychopharmacology. 14:1996;87-96.
12. Calabrese J.R., Kimmel S.E., Woyshville M.J., Rapport D.J., Faust C.J., Thompson P.A., Meltzer H.Y. Clozapine for treatment-refractory mania. Am. J. Psychiatry. 153:1996;759-764.
13. Ceskova E., Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 26:1993;121-124.
14. Dwight M.M., Keck P.E. Jr., Stanton S.P.et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet. 344:1994;554-555.
15. 3H-kitanserin recognition sites Life Sci. 36:1984;713-721.
16. Goldstein J.M., Arvanitis L.A. ICI 204,636 (Seroquel™): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev. 1:1995;50-73.
17. Harrington M.A., Zhong P., Garlow S.et al. Molecular biology of serotonin receptors. J. Clin. Psychiatry. 53(Suppl. 10):1992;8-27.
18. Hillert A., Maier W., Wetzel H.et al. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: a functional approach. Pharmacopsychiatry. 25:1992;213-217.
19. Hingtgen J.N., Hendrie H.C., Aprison M.H. Postsynaptic serotonergic blockade following chronic antidepressive treatment with trazodone in an animal model of depression. Pharmacol. Biochem. Behav. 20:1983;425-428.
20. Hirschfeld R.M.A. Schizoaffective disorders and psychotic mania. Psychiatr. Ann. 26(Suppl.):1996;435-439.
21. Janicak, P.G., Davis, J.M., Preskorn, S.H. et al. (Eds.), 1993. Principles and Practice of Psychopharmacotherapy. Williams and Wilkins, Baltimore, MD, pp. 86-87.
22. Kane J.M., Honigfeld G., Singer J.et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
23. Kasper S., Praschak-Rieder N., Tauscher J.et al. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf. 4:1997;251-264.
24. Kaspur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry. 153:1996;466-476.
25. Keck P.E. Jr., McElroy S.L., Strakowski S.M., West S.A. Pharmacologic treatment of schizoaffective disorder. Psychopharmacology (Berl.). 114:1994;529-538.
26. Keck P.E. Jr., Wilson D.R., Strakowski S.M.et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J. Clin. Psychiatry. 56:1995;466-470.
27. Keck P.E. Jr., McElroy S.L., Strakowski S.M. New developments in the pharmacologic treatment of schizoaffective disorder. J. Clin. Psychiatry. 57(Suppl. 9):1996;41-48.
28. Keck P.E. Jr., McElroy S.L. The new antipsychotics and their therapeutic potential. Psychiatr. Ann. 27:1997;320-331.
29. Keck Jr., P.E., Harrigan, E.P., Reeves, K.R., 1997a. The efficacy of ziprasidone in schizophrenia and schizoaffective disorder: an update. Biol. Psychiatry 42 (Suppl.), 42S.
30. Keck Jr., P.E., Reeves, K.R., Harrigan, E.P., 1997b. Ziprasidone: an overview of efficacy and tolerability in the treatment of patients with acute exacerbation of schizophrenia or schizoaffective disorder. In: Abstracts of the 37th Annual Meeting of the NCDEU, Boca Raton, FL, May 27-30.
31. Lindstrom L.H. A retrospective study of the long-term efficacy and safety of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology (Berl.). 99(Suppl.):1989;84-86.
32. Lu, Y., Sanger, T., Beasley, C. et al., 1995. Olanzapine in the treatment of schizoaffective disorder. In: Abstracts of the 34th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR, December 11-15.
33. Madhusoodanan S., Brenner R., Arauju L.et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J. Clin. Psychiatry. 56:1995;514-518.
34. Malhotra, A.K., Litman, R.E., Su, T.P. et al., 1993. Clozapine response in schizoaffective disorder. In: New Research Program and Abstracts of the 146th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 24, NR 53, p. 73.
35. McElroy S.L., Dessain E.C., Pope H.G. Jr.et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry. 52:1991;411-414.
36. McElroy S.L., Keck P.E. Jr. Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can. J. Psychiatry. 38(Suppl. 2):1993;62-66.
37. Moore N.A., Calligaro D.O., Wong B.T.et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Invest. Drugs. 2:1993;281-293.
38. Naber D., Hippius H. The European experience with the use of clozapine. Hosp. Community Psychiatry. 41:1990;886-890.
39. Okuma T., Yamaskita I., Takahashi R.et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr. Scand. 80:1989;250-259.
40. Pandey G.N., Pandey S.C., Janicak P.G.et al. Platelet serotonin-2 receptor binding sites in depression and suicide. Biol. Psychiatry. 28:1990;215-222.
41. 3H] spiroperidol by chronic treatment with the antidepressant amitriptyline J. Pharmacol. Exp. Ther. 215:1980;582-587.
42. Potter, W.Z., Manji, H.K., Rudorfer, M.V., 1995. Tricyclics and tetracyclics. In: Schatzberg, A.F., Nemeroff, C.B. (Eds.), Textbook of Psychopharmacology. American Psychiatric Press, Washington, DC, pp. 141-160.
43. Rothschild, A.J., Bates, K.S., Boehringer, K. et al., 1997. Olanzapine response in psychotic depression. In: Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, HI, December 10.
44. Sajatovic M., DiGiovanni S.K., Bastani B.et al. Risperidone therapy in the treatment of refractory acute bipolar and schizoaffective mania. Psychopharmacol. Bull. 32:1996;55-61.
45. Seeger T.F., Seymour P.A., Schmidt A.W.et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 275:1995;101-113.
46. Simhandl C., Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review. J. Psychiatry Neurosci. 17:1992;1-14.
47. Siris, S.G., 1993. The treatment of schizoaffective disorder. In: Dunner, D.L. (Ed.), Current Psychiatry Therapy. W.B. Saunders, Philadelphia, pp. 160-165.
48. Stefanowicz P. Initial results of clozapine and lithium treatment of manic syndromes in the course of schizoaffective psychosis. Psychiatr. Pol. 24:1990;27-30.
49. Suppes T., McElroy S.L., Gilbert J.et al. Clozapine in the treatment of dysphoric mania. Biol. Psychiatry. 32:1992;270-280.
50. Suppes T., Phillips K.A., Judd C.R. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol. Psychiatry. 36:1994;338-340.
51. Tohen, M., Sanger, T., Tollefson, G.D. et al., 1997. Olanzapine vs. placebo in the treatment of acute mania. In: Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, HI, December 10.
52. Tollefson G.D., Beasley C.M. Jr., Tran P.V.et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of the international collaborative trial. Am. J. Psychiatry. 154:1997;457-465.
53. Tollefson G.D., Sanger T.M., Lu Y., Thieme M.E. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch. Gen. Psychiatry. 55:1998;250-258.
54. Williams J.B.W., Gibbon M., First M.B.et al. The structured clinical interview for DSM-III-R (SCID). II: multisite test-retest reliability. Arch. Gen. Psychiatry. 49:1992;630-636.
55. 2 receptor changes in major depression. Biol. Psychiatry. 27:1990;489-496.
56. Zarate C.A. Jr., Tohen M., Baldessarini R.J. Clozapine in severe mood disorders. J. Clin. Psychiatry. 56:1995;411-417.